Avidity to Showcase Breakthrough DMD44 Data at WMS
Avidity Biosciences, Inc. is set to present significant data at the 30th Annual International Congress of the World Muscle Society (WMS) in Vienna, Austria, from October 7-11, 2025. The company, headquartered in San Diego, CA, will showcase its progress in treating Duchenne muscular dystrophy (DMD) amenable to exon 44 skipping (DMD44) using its novel RNA therapeutic, delpacibart zotadirsen (del-zota).
Dr. Kevin M. Flanigan, M.D., from Nationwide Children's Hospital, will deliver an oral presentation on October 11, 2025, from 12:33 - 12:45 p.m. CET, detailing the positive results from Avidity's Phase 1/2 EXPLORE44 and Phase 2 EXPLORE44-OLE trials. These trials demonstrated that del-zota increased dystrophin and improved muscle integrity markers regardless of ambulatory status in individuals with DMD44.
Additionally, Dr. Aravindhan Veerapandiyan, M.D., will present a poster on October 8, 2025, from 2:30 - 3:30 p.m. CET, further elaborating on these findings. Both presentations and posters will be available on Avidity's website at https://www.aviditybiosciences.com.
Avidity's commitment to delivering a new class of RNA therapeutics, called Antibody Oligonucleotide Conjugates (AOCsTM), is evident in its leadership of clinical development programs for three rare muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD). The data to be presented at WMS reinforces and builds on the positive results from Avidity's trials, showing trends toward improvement in functional and patient-reported outcomes in individuals with DMD44.
Read also:
- Overweight women undergoing IVF have a 47% higher chance of conceiving naturally post-weight loss
- Bonsai Trees from Evergreen Species: Exploring Growth Characteristics & Distinct Qualities
- What temperatures may make walking your canine companion uncomfortable?
- Title: Information About Beovu: Potency, Form, Usage, and Additional Details
